Jump to content

Surly #Stonks


Wally Fairway

Recommended Posts

18 minutes ago, 0xdeadbeef said:

Almost 95% of my portfolio is in AI and semiconductor stocks and ETFs.   My way of diversifying is I just I bought a small amount of IBRX at $6.9092.  

Show me what you got.

Let's see if it can out grow NVDA.

 

 

I doubt NVDA can 20x from $3tn in the next few years 

I’ve got my now 40k shares at a GTC of $50 so they can’t be borrowed.   

Link to comment
Share on other sites

1 hour ago, Trey3216 said:

I doubt NVDA can 20x from $3tn in the next few years 

True, but a company like IBRX could hit it big, flounder in testing purgatory, or go out of business.  Two of those paths won't surpass NVDA returns.  Let's hope for the change-the-world cancer cure.

 

 

 

 

Edited by 0xdeadbeef
Link to comment
Share on other sites

14 hours ago, 3adays said:

Anyone in here own CYBL? I pretty sure I bought it based off this thread and had totally forgotten I had it. It has been on a nice little run lately and I was curious if anyone knew why. 

Most stocks in that price range run because they need to dump more shares (dilution). Typically, they are out of money and generate momentum to get people to buy, thinking it’s going to the moon. I don’t know any specifics on this particular ticker.

  • Hook 'Em 1
Link to comment
Share on other sites

2 hours ago, WBT said:

Knew it was a stonk

Always a good sign when your auditor says "fuck this shit, I'm out" 

And speaking of stonks, I see CVNA is up 20% after their earnings release. If the after hours move holds up, they will open up tomorrow with a market cap approximately the same size as GM (and larger than Ford). They made $140M in profit this quarter. GM just reported $3B in profit. How many fucking cars do people expect them to sell at a 4% margin in the future to justify that valuation? But Ive been thinking that about CVNA for a while now, and it shows no signs of sanity returning. Will be up about 25X in the last year and a half.  

image.png.a6222f0e717665af2e6e38d5519d48fd.png

Link to comment
Share on other sites

On 10/27/2024 at 8:23 AM, 3adays said:

Anyone in here own CYBL? I pretty sure I bought it based off this thread and had totally forgotten I had it. It has been on a nice little run lately and I was curious if anyone knew why. 

I own CYBL. It had been tagged with the caveat emptor label for a while. When that got lifted it ran up to about .01. Then they announced a $22 million contract with the government, and it ran up to .02.  It has since settled back to around a penny. Hopefully they get a few more contracts, and it goes on another run. I’m in for 300,000 shares at .002 so nothing major, but it’s nice to be in the green again.

  • Hook 'Em 1
Link to comment
Share on other sites

Two retired business men are chatting at a tropical beach bar.

One says to the other, “when my widget factory burnt down I didn’t rebuild took the insurance payment and retired”.

Second says, “ oh, my I did the exact same thing when my widget factory was destroyed by a tornado.”

First business man sits quietly for a moment with a confused look on his face and then asks, “how do you start a tornado?”

  • Hook 'Em 1
  • Like 1
  • Haha 4
Link to comment
Share on other sites

Last Friday premarket, Energy Fuels (UUUU) reported a miss with Q3 earnings and the stock dropped from $6.05 to a low Monday of $5.36.   UUUU has recovered currently trading at $6.28.  UUUU continues to actively expand their facilities increasing capacity to produce more uranium, rare earths, and medical Isotopes in 2025 while sitting on supplies of finished uranium and vanadium waiting for uranium prices to go up. They have plenty of cash ($1.21/sh, $234 million) and no debt.

Yesterday, EOSE reported a miss with Q3 earnings due to temporary supply chain issues and the stock dropped from $3.20 to $2.26.  EOSE has recovered some currently trading at $2.85 (blessed are the dip buyers).  No one expected them to be profitable yet.  This is a 2025 story.

  • Hook 'Em 1
Link to comment
Share on other sites

Governor Abbott, PUCT Release Texas Advanced Nuclear Reactor Working Group Report

November 18, 2024 | Austin, Texas | Press Release

Governor Greg Abbott and the Public Utility Commission of Texas (PUCT) today announced the release of the Texas Advanced Nuclear Reactor Working Group’s final report on Texas’ plan to build a world-leading advanced nuclear power industry to enhance electric reliability and energy security, promote economic development, and unleash new opportunities for the growing Texas workforce.
 
“Texas is the energy capital of the world, and we are ready to be No. 1 in advanced nuclear power,” said Governor Abbott. “By utilizing advanced nuclear energy, Texas will enhance the reliability of the state grid and provide affordable, dispatchable power to Texans across the state. I thank Public Utility Commissioner Jimmy Glotfelty and the members of the Texas Advanced Nuclear Reactor Working Group for working tirelessly to put Texas on the path to be the global leader in advanced nuclear power. As we build an advanced nuclear industry in our great state, we will ensure Texas remains a leader in energy and strengthen the Texas grid to meet the demands of our growing state.”
 
“Texas has long been the energy capital of the world, and today we have an incredible opportunity to build a world-leading advanced nuclear industry that will deliver safe, reliable power for generations to come,” PUCT Commissioner Jimmy Glotfelty said. “I want to thank the Governor for his direction on this important issue and the many people who dedicated their time and expertise to this work. The economic and policy recommendations we’ve outlined will inspire swift action and help Texas become the leader in advanced nuclear energy.” 
 
In August 2023, Governor Abbott directed the PUCT to form a working group to study and plan for the use of advanced nuclear reactors in Texas. Over the past year, the working group developed key recommendations and strategies to position Texas as No. 1 in the advanced nuclear industry.

———————————————————————————————————————————————————————————————————————————————

UUUU +.65 to $7.29.  Looking hard at additional uranium exposure with UEC (+.86 to $8.28) which is headquartered in Corpus Christi.

  • Hook 'Em 1
  • Like 2
Link to comment
Share on other sites

2 hours ago, MonkeyDoughnut said:

Could be day with more movement... sitting right at $5 currently

Key quote from the article:

This significant milestone underscores the potential of ANKTIVA to provide durable responses in patients with limited treatment options. The QUILT 3.032 study is a single-arm, multicenter trial evaluating the safety and efficacy of ANKTIVA plus BCG in patients with BCG-unresponsive NMIBC CIS. The observed 71% CR rate aligns with previous findings reported in the New England Journal of Medicine (NEJM Evidence, Chamie 2022) and reinforces the therapeutic promise of this combination therapy.

“We are encouraged by the consistent complete response rates observed in our expanded patient cohort,” said Patrick Soon-Shiong, M.D., Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio. “These results highlight the potential of ANKTIVA to transform the treatment landscape for patients with BCG-unresponsive NMIBC CIS, offering hope for improved outcomes and cystectomy avoidance, especially with the prolonged duration of response now ranging as much as 54 months in this 100-patient analysis. Duration of complete response is the key efficacy element in driving cystectomy avoidance in this BCG-unresponsive population. I am pleased that this updated ANKTIVA data confirms that one of the highest durable responses is achieved when compared to other approved products in this indication.”

The QUILT 3.032 study continues to monitor patients to assess the durability of responses and overall survival outcomes. ImmunityBio remains committed to advancing innovative immunotherapies that harness the body's immune system to combat cancer.

https://www.crweworld.com/article/news-provided-by-business-wire/3533364/immunitybio-completes-anktivas-post-approval-enrollment-of-the-100th-patient-in-bcg-unresponsive-nmibc-cis-trial-and-reports-a-complete-response-rate-of-71-with-a-durable-duration-of-response-ranging-up-to-54-months#google_vignette

  • Hook 'Em 1
Link to comment
Share on other sites

1 hour ago, KYHorn said:

Key quote from the article:

This significant milestone underscores the potential of ANKTIVA to provide durable responses in patients with limited treatment options. The QUILT 3.032 study is a single-arm, multicenter trial evaluating the safety and efficacy of ANKTIVA plus BCG in patients with BCG-unresponsive NMIBC CIS. The observed 71% CR rate aligns with previous findings reported in the New England Journal of Medicine (NEJM Evidence, Chamie 2022) and reinforces the therapeutic promise of this combination therapy.

“We are encouraged by the consistent complete response rates observed in our expanded patient cohort,” said Patrick Soon-Shiong, M.D., Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio. “These results highlight the potential of ANKTIVA to transform the treatment landscape for patients with BCG-unresponsive NMIBC CIS, offering hope for improved outcomes and cystectomy avoidance, especially with the prolonged duration of response now ranging as much as 54 months in this 100-patient analysis. Duration of complete response is the key efficacy element in driving cystectomy avoidance in this BCG-unresponsive population. I am pleased that this updated ANKTIVA data confirms that one of the highest durable responses is achieved when compared to other approved products in this indication.”

The QUILT 3.032 study continues to monitor patients to assess the durability of responses and overall survival outcomes. ImmunityBio remains committed to advancing innovative immunotherapies that harness the body's immune system to combat cancer.

https://www.crweworld.com/article/news-provided-by-business-wire/3533364/immunitybio-completes-anktivas-post-approval-enrollment-of-the-100th-patient-in-bcg-unresponsive-nmibc-cis-trial-and-reports-a-complete-response-rate-of-71-with-a-durable-duration-of-response-ranging-up-to-54-months#google_vignette

Also read some of PSS' comments about a trial they did on folks with elevated PSA levels....6 weeks in and PSA levels were dropping to near zero.   They get a full trial and approval for that.....

 

200w.gif?cid=6c09b952wu9gz2nafey38odg791

  • Hook 'Em 2
Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.



×
×
  • Create New...